These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25761856)

  • 1. Addressing limitations in observational studies of the association between glucose-lowering medications and all-cause mortality: a review.
    Patorno E; Garry EM; Patrick AR; Schneeweiss S; Gillet VG; Zorina O; Bartels DB; Seeger JD
    Drug Saf; 2015 Mar; 38(3):295-310. PubMed ID: 25761856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations.
    Patorno E; Patrick AR; Garry EM; Schneeweiss S; Gillet VG; Bartels DB; Masso-Gonzalez E; Seeger JD
    Diabetologia; 2014 Nov; 57(11):2237-50. PubMed ID: 25212258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose-lowering medications and the risk of cancer: A methodological review of studies based on real-world data.
    Bykov K; He M; Franklin JM; Garry EM; Seeger JD; Patorno E
    Diabetes Obes Metab; 2019 Sep; 21(9):2029-2038. PubMed ID: 31062453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between pacifier use and breast-feeding, sudden infant death syndrome, infection and dental malocclusion.
    Callaghan A; Kendall G; Lock C; Mahony A; Payne J; Verrier L
    Int J Evid Based Healthc; 2005 Jul; 3(6):147-67. PubMed ID: 21631747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Commonly used diabetes and cardiovascular medications and cancer recurrence and cancer-specific mortality: a review of the literature.
    Wu JW; Boudreau DM; Park Y; Simonds NI; Freedman AN
    Expert Opin Drug Saf; 2014 Aug; 13(8):1071-99. PubMed ID: 24999107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication safety research by observational study design.
    Lao KS; Chui CS; Man KK; Lau WC; Chan EW; Wong IC
    Int J Clin Pharm; 2016 Jun; 38(3):676-84. PubMed ID: 27003827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
    Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
    Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of short-term exposure to air pollution on hospital admissions of young children for acute lower respiratory infections in Ho Chi Minh City, Vietnam.
    ; Le TG; Ngo L; Mehta S; Do VD; Thach TQ; Vu XD; Nguyen DT; Cohen A
    Res Rep Health Eff Inst; 2012 Jun; (169):5-72; discussion 73-83. PubMed ID: 22849236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of antimicrobial de-escalation on mortality: a literature review of study methodology and recommendations for observational studies.
    Van Heijl I; Schweitzer VA; Van Der Linden PD; Bonten MJM; Van Werkhoven CH
    Expert Rev Anti Infect Ther; 2020 May; 18(5):405-413. PubMed ID: 32178545
    [No Abstract]   [Full Text] [Related]  

  • 12. Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure.
    Walker JJ; Johnson JA; Wild SH
    Lancet Diabetes Endocrinol; 2013 Oct; 1(2):132-9. PubMed ID: 24622319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome association.
    Gruber S; Chakravarty A; Heckbert SR; Levenson M; Martin D; Nelson JC; Psaty BM; Pinheiro S; Reich CG; Toh S; Walker AM
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):973-81. PubMed ID: 27418432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-to-event methodology improved statistical evaluation in register-based health services research.
    Bluhmki T; Bramlage P; Volk M; Kaltheuner M; Danne T; Rathmann W; Beyersmann J
    J Clin Epidemiol; 2017 Feb; 82():103-111. PubMed ID: 27845180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Observational research--opportunities and limitations.
    Boyko EJ
    J Diabetes Complications; 2013; 27(6):642-8. PubMed ID: 24055326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of intensive glucose lowering in treatment of type 2 diabetes mellitus on cardiovascular outcomes: A meta-analysis of data from 58,160 patients in 13 randomized controlled trials.
    Fang HJ; Zhou YH; Tian YJ; Du HY; Sun YX; Zhong LY
    Int J Cardiol; 2016 Sep; 218():50-58. PubMed ID: 27236108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
    Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
    JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.